Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women’s health.
2005
26
LTM Revenue $1.3M
LTM EBITDA n/a
$16.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dare Bioscience has a last 12-month revenue of $1.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Dare Bioscience achieved revenue of $2.8M and an EBITDA of -$30.9M.
Dare Bioscience expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Dare Bioscience valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $10.0M | $2.8M | $1.1M | $1.3M | XXX |
Gross Profit | n/a | n/a | n/a | XXX | XXX |
Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
EBITDA | -$31.4M | -$30.9M | n/a | n/a | XXX |
EBITDA Margin | -314% | -1101% | NaN% | 0% | XXX |
Net Profit | -$38.7M | -$30.9M | -$30.2M | XXX | XXX |
Net Margin | -387% | -1102% | -2793% | XXX | XXX |
Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 10, 2025, Dare Bioscience's stock price is $3.
Dare Bioscience has current market cap of $25.9M, and EV of $16.0M.
See Dare Bioscience trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$16.0M | $25.9M | XXX | XXX | XXX | XXX | $-0.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 10, 2025, Dare Bioscience has market cap of $25.9M and EV of $16.0M.
Dare Bioscience's trades at 12.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Dare Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Dare Bioscience and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $16.0M | XXX | XXX | XXX |
EV/Revenue | 14.9x | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | XXX | XXX |
P/E | -8.7x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDare Bioscience's NTM/LTM revenue growth is 476%
Dare Bioscience's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Dare Bioscience's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Dare Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Dare Bioscience and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | -62% | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 431% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 767% | XXX | XXX | XXX | XXX |
Opex to Revenue | 1202% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dare Bioscience acquired XXX companies to date.
Last acquisition by Dare Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Dare Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Dare Bioscience founded? | Dare Bioscience was founded in 2005. |
Where is Dare Bioscience headquartered? | Dare Bioscience is headquartered in United States of America. |
How many employees does Dare Bioscience have? | As of today, Dare Bioscience has 26 employees. |
Who is the CEO of Dare Bioscience? | Dare Bioscience's CEO is Ms. Sabrina Martucci Johnson. |
Is Dare Bioscience publicy listed? | Yes, Dare Bioscience is a public company listed on NAS. |
What is the stock symbol of Dare Bioscience? | Dare Bioscience trades under DARE ticker. |
When did Dare Bioscience go public? | Dare Bioscience went public in 2014. |
Who are competitors of Dare Bioscience? | Similar companies to Dare Bioscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Dare Bioscience? | Dare Bioscience's current market cap is $25.9M |
What is the current revenue of Dare Bioscience? | Dare Bioscience's last 12-month revenue is $1.3M. |
What is the current EV/Revenue multiple of Dare Bioscience? | Current revenue multiple of Dare Bioscience is 12.1x. |
What is the current revenue growth of Dare Bioscience? | Dare Bioscience revenue growth between 2023 and 2024 was -62%. |
Is Dare Bioscience profitable? | Yes, Dare Bioscience is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.